Valion Bio, Inc. (VBIO)
2.37
-0.13
(-5.20%)
USD |
NASDAQ |
Sep 09, 09:55
Valion Bio Enterprise Value : 23.36M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 23.36M |
| September 04, 2026 | 23.40M |
| September 03, 2026 | 23.41M |
| September 02, 2026 | 23.46M |
| September 01, 2026 | 23.45M |
| August 31, 2026 | 23.53M |
| August 28, 2026 | 23.44M |
| August 27, 2026 | 23.45M |
| August 26, 2026 | 23.59M |
| August 25, 2026 | 23.60M |
| August 24, 2026 | 23.63M |
| August 21, 2026 | 23.45M |
| August 20, 2026 | 23.45M |
| August 19, 2026 | 23.50M |
| August 18, 2026 | 23.61M |
| August 17, 2026 | 23.70M |
| August 14, 2026 | 23.73M |
| August 13, 2026 | 23.65M |
| August 12, 2026 | 23.88M |
| August 11, 2026 | 24.23M |
| August 10, 2026 | 24.14M |
| August 07, 2026 | 24.13M |
| August 06, 2026 | 24.08M |
| August 05, 2026 | 24.15M |
| August 04, 2026 | 24.32M |
| Date | Value |
|---|---|
| August 03, 2026 | 24.25M |
| July 31, 2026 | 24.23M |
| July 30, 2026 | 24.09M |
| July 29, 2026 | 24.10M |
| July 28, 2026 | 24.14M |
| July 27, 2026 | 24.11M |
| July 24, 2026 | 24.17M |
| July 23, 2026 | 24.13M |
| July 22, 2026 | 24.12M |
| July 21, 2026 | 24.23M |
| July 20, 2026 | 24.44M |
| July 17, 2026 | 25.04M |
| July 16, 2026 | 24.97M |
| July 15, 2026 | 24.81M |
| July 14, 2026 | 24.89M |
| July 13, 2026 | 25.05M |
| July 10, 2026 | 25.05M |
| July 09, 2026 | 25.02M |
| July 08, 2026 | 24.97M |
| July 07, 2026 | 25.07M |
| July 06, 2026 | 25.05M |
| July 02, 2026 | 25.01M |
| July 01, 2026 | 25.09M |
| June 30, 2026 | 25.10M |
| June 29, 2026 | 18.89M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Outlook Therapeutics, Inc. | 127.02M |
| Agenus, Inc. | 581.29M |
| Amgen, Inc. | 255.86B |
| Anika Therapeutics, Inc. | 268.42M |
| BioCryst Pharmaceuticals, Inc. | 2.798B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.057M |
| Total Expenses (Quarterly) | 7.057M |
| EPS Diluted (Quarterly) | -52.54 |
| Earnings Yield | -8.87K% |
| Normalized Earnings Yield | -8888.79 |